FP 025

Drug Profile

FP 025

Alternative Names: FP-003; FP-025

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator Foresee Pharmaceuticals
  • Class Antiasthmatics
  • Mechanism of Action Matrix metalloproteinase 12 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 05 Apr 2017 Foresee Pharmaceuticals plans a phase IIa proof-of-concept trial for Asthma
  • 05 Sep 2014 Foresee Pharmaceuticals plans a phase I trial of FP 025 in Healthy volunteers in USA (NCT02238834)
  • 31 Jan 2013 Preclinical trials in Asthma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top